ArticleJournal of neurochemistry2025
Exploring the Gut and Oral Microbiomes in Psychoactive Substance Use: A Scoping Review of Clinical Studies.
Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GutGut microbes · 2026Article
- Preface to the Special Issue: "Microbiota and Gut-Brain Axis".Journal of neurochemistry · 2026Article
- Exploring the Gut and Oral Microbiomes in Psychoactive Substance Use: A Scoping Review of Clinical Studies.Journal of neurochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substance use disorders (SUDs) constitute a significant global health challenge, and emerging evidence suggests that the gut and oral microbiomes may play significant roles in addiction pathophysiology, yet the human clinical literature remains fragmented. This scoping review systematically synthesizes evidence from 75 clinical studies investigating alterations in gut and oral microbiomes associated with alcohol, stimulant, cannabis, and opioid use. Across studies, beta-diversity analyses frequently reveal clear differences between substance users and controls, indicating distinct community structures. Findings on alpha diversity and specific taxonomic shifts vary by substance. Commonly observed changes included declines in beneficial short-chain fatty acid-producing taxa, alongside expansions of opportunistic or proinflammatory microorganisms. However, substantial methodological heterogeneity, including variations in study design, population characteristics, and analytical methods, complicates direct comparisons and definitive conclusions. Limited longitudinal evidence indicates partial microbiome recovery after extended abstinence, although full restoration remains uncertain. Further longitudinal research with standardized methods is needed to clarify these findings and inform potential microbiome-targeted therapies for SUDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.